AbbVie: Lymphoma, Follicular trials
The registry lists 23 Lymphoma, Follicular studies with AbbVie as lead sponsor. 1 are open to participants now and 15 have results posted.
Phase 1 10Phase 2 10Phase 3 7No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular LymphomaRecruitingNCT06830759
- Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative ColitisTerminatedNCT05785715Phase 2Results posted
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaCompletedNCT02947347Phase 3Results posted
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory LymphomasCompletedNCT02401048Phase 1/2Results posted
- Patient Experience Study of Deoxycholic Acid InjectionCompletedNCT02007434Phase 3Results posted
- Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedNCT01546142Phase 3Results posted
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedNCT01542034Phase 3Results posted
- Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedNCT01426373Phase 3Results posted
- Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental FatCompletedNCT01305577Phase 3Results posted
- Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental FatCompletedNCT01294644Phase 3Results posted
- Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01109069Phase 2Results posted
- Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures StudyCompletedNCT01032889Phase 2Results posted
- Study of the Safety and Tolerability of PCI-24781 in Patients With LymphomaCompletedNCT00724984Phase 1/2Results posted
- Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedNCT00618722Phase 1/2Results posted
- Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedNCT00618618Phase 2Results posted
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaActive, not recruitingNCT06667687Phase 1
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive, not recruitingNCT05753501Phase 1
- A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT05512390Phase 1
- Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
- Study Evaluating ABT-414 in Japanese Subjects With Malignant GliomaCompletedNCT02590263Phase 1/2
- Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1
- A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2